Dr. Reddy's Delays Semaglutide Supplies Amid API Quality Issues, Resumes Expected by November
Dr. Reddy's Laboratories has halted commercial supplies of its generic semaglutide due to quality issues linked to impurities found in the active pharmaceutical ingredient (API) during scale-up production. The company expects to resume shipments by late October or November after completing validation and resolving the issue. While patient safety and existing regulatory approvals remain unaffected, the supply disruption has led to reduced production targets for FY27 and prompted recalls by partners Torrent Pharmaceuticals and USV Ltd. Despite near-term challenges, demand for semaglutide remains strong, with expectations of recovery and growth in subsequent years.
First-hand measurement across 13 sources
We measured how 13 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is neutral (45/100). Lens Score 30/100.
Outlets measured: thefinancialexpress, economictimes, businessstandard, economictimes, economictimes, thehindu, thehindu, mint, and 5 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 13 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment was consistent across outlets (40–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 9 Jul, 04:18 am. Other outlets followed.